Glaxosmithkline Pharmaceuticals Ltd vs Medico Intercontinental Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2450 as of 07 May 09:19 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Medico Intercontinental Ltd changed from 3.2 on March 2021 to 7 on March 2025 . This represents a CAGR of 16.95% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Medico Intercontinental Ltd changed from ₹ 8.33 crore on March 2021 to ₹ 35.47 crore on March 2025 . This represents a CAGR of 33.61% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Medico Intercontinental Ltd for the Dec '25 is ₹ 20.19 crore as compare to the Sep '25 revenue of ₹ 20.95 crore. This represent the decline of -3.63% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Medico Intercontinental Ltd for the Dec '25 is ₹ 1.93 crore as compare to the Sep '25 ebitda of ₹ -0.33 crore. This represent the decline of -684% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Medico Intercontinental Ltd changed from ₹ 1.08 crore to ₹ -1.68 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Medico Intercontinental Ltd changed from 5.88 % on March 2023 to 0 % on March 2025 . This represents a CAGR of -100.00% over 3 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Medico Intercontinental Ltd

Medico Intercontinental Limited, formerly known as Intercontinental Leasing & Finance Company Limited was incorporated on August 14, 1984 in Ahmedabad, India.
The Company changed its name to 'Medico Intercontinental Limited' in December, 2018.
The Company is involved in trading of pharmaceutical products. The Company is also providing a platform to all research based bio-pharmaceutical companies reaching their novel and innovative therapies to every part of the globe.
From helping people obtain their medications to using cutting-edge scientific technology to discover new treatments, Medico's entrepreneurial spirit, teamwork-oriented culture and commitment to rare diseases create a unique platform for transforming patient outcomes.
The Company's commitment to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first across the continents.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Medico Intercontinental Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Medico Intercontinental Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,069 Cr while Market cap of Medico Intercontinental Ltd is 23 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Medico Intercontinental Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Medico Intercontinental Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Medico Intercontinental Ltd?

As of May 7, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2424.3. On the other hand, Medico Intercontinental Ltd stock price is INR ₹23.13.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Medico Intercontinental Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Medico Intercontinental Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.